Eli Lilly and Company
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Eli Lilly and Company sits in the top decile of US sponsors by registered trial count (#18 of 15,742 sponsors by registered trial count).
Eli Lilly and Company: 1,341 sponsored US clinical trials, 124 recruiting.
Eli Lilly and Company sponsors 1,341 registered US clinical trials on ClinicalTrials.gov, 124 of them currently recruiting, and 1,029 completed. 459 of these trials are in Phase 3-4 (later-stage) and 861 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 55 trials.
Top-decile sponsor footprint
Eli Lilly and Company ranks in the top decile of sponsors by registered trial count (#18 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,029 of 1,131 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,341 total, page 19 of 27
A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy
NCT01185353
A Study of Duloxetine in Elderly Generalized Anxiety Disorder
NCT01118780
A Study of LY900010 in Erectile Dysfunction
NCT01160289
A Study of Olaratumab in Soft Tissue Sarcoma
NCT01185964
A Study to Measure if There is Any Difference in How the Body Breaks Down or Inactivates Either Fluoxetine or LY2216684 When Both of These Medicines Are Given Together.
NCT01243957
A Study in Benign Prostatic Hyperplasia
NCT01152190
A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT01160744
A Study in Advanced Cancer
NCT01226485
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
NCT01139762
A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's
NCT01148498
A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
NCT01087970
A Study in Erectile Dysfunction
NCT01130532
A Study of LY2541546 in Women With Low Bone Mineral Density
NCT01144377
A Study of Ramucirumab or Icrucumab in Colorectal Cancer
NCT01111604
Prasugrel Versus Placebo in Adult Sickle Cell Disease
NCT01167023
Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer
NCT01109524
Notch Inhibitor in Advanced Cancer
NCT01158404
A Study in Participants With Diabetic Kidney Disease
NCT01113801
An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma
NCT01137006
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
NCT01149421
A Safety Study of LY2886721 Single Doses in Healthy Subjects
NCT01133405
A Study in Advanced Solid Tumors
NCT01063075
A Study in Head and Neck Cancer
NCT01081041
A Study of LY2624587 in Patients With Advanced Cancer
NCT01139788
A Long-Term, Open-Label, Study on Schizophrenia
NCT01129674
Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer
NCT01107444
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)
NCT01126580
A Study of IMC-RON8 in Advanced Solid Tumors
NCT01119456
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
NCT01131104
A Study of LY2875358 in Participants With Advanced Cancer
NCT01287546
A Study in Participants With Moderate to Severe Psoriasis
NCT01107457
Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use
NCT01109316
Study in Advanced Solid Tumors
NCT01099358
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
NCT01105975
A Study in Myeloproliferative Disorders
NCT01134120
A Study in Men With Benign Prostatic Hyperplasia
NCT01097707
A Study in Schizophrenia Patients
NCT01086748
Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome
NCT01088503
Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight With Coronary Artery Disease
NCT01107925
Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease
NCT01107912
A Study in Depression and Associated Painful Physical Symptoms
NCT01070329
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
NCT01115803
A Study in Participants With Type 2 Diabetes Mellitus
NCT01064687
A Phase 1 Study in Participants With Advanced Cancer
NCT01115790
First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin
NCT00981058
A Phase 1 Study of LY2787106 in Cancer and Anemia
NCT01340976
A Study for Patients With Type 2 Diabetes
NCT01027871
A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT00918203
A Study for Patients With Type 1 Diabetes
NCT01049412
A Phase 1 Study of LY2835219 In Participants With Advanced Cancer
NCT01394016
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 517 |
| Phase 2 | 344 |
| Phase 3 | 368 |
| Phase 4 | 91 |
Therapeutic Areas
What is open in the Eli Lilly and Company pipeline
124 recruiting of 1,341 indexed (9% open); 1,029 completed (77%).
Phase mix: 459 late (III/IV) vs 861 early (I/II) (early-phase heavy).
Top condition: Healthy (55 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Eli Lilly and Company: open-pipeline peers nationwide
Peers matched on 1,341 registered trials and 9% open enrollment, not the therapeutic-area sidebar.
Eli Lilly and Company sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,341 trials (± recruiting share)
- GlaxoSmithKline · 1,345 trials · 4% recruiting
- University of Michigan · 1,327 trials · 13% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
- AstraZeneca · 1,285 trials · 12% recruiting
Sponsors near 9% open enrollment (± trial volume)
- Shionogi · 9% recruiting · 54 trials
- University of Kentucky · 9% recruiting · 54 trials
- University of Vermont · 9% recruiting · 162 trials
- Lahey Clinic · 9% recruiting · 43 trials
Related
What to do with this Eli Lilly and Company page
1,341 registered trials is a research-attention snapshot, not an endorsement of Eli Lilly and Company or any single study.
- 124 of Eli Lilly and Company's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition Eli Lilly and Company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Eli Lilly and Company pipeline card: 1,341 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.